46 completed, 20 unknown, 6 terminated, 5 active not recruiting. 86 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 86 | Completed 46, Unknown 20, Terminated 6, Active not recruiting 5, Recruiting 5, Withdrawn 3, Not yet recruiting 1 |
| Phase 2 | 5 | Completed 2, Terminated 2, Unknown 1 |
Follow Lymphoma, Mantle-Cell: new trials by email Literature Review of Lymphoma, Mantle-Cell trials Research Report on Lymphoma, Mantle-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL). ICP-248, Pirtobrutinib, Orelabrutinib - Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Phase 3 | Not yet recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | 280 | 2026-10-01 | 2026-08-25 |
| A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma Rocbrutinib, Ibrutinib, Acalabrutinib - Mantle Cell Lymphoma | Phase 3 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 394 | 2026-02-05 | 2026-02-06 |
| A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) Sonrotoclax, Zanubrutinib, Placebo - Mantle Cell Lymphoma, B Cell Lymphoma | Phase 3 | Recruiting | BeOne Medicines | 300 | 2025-03-05 | 2026-10-29 |
| Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment Orelabrutinib, Bendamustine, Rituximab - Mantle Cell Lymphoma (MCL) | Phase 3 | Recruiting | Ruijin Hospital | 78 | 2024-07-10 | 2024-07-11 |
| A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL Orelabrutinib, Bendamustine Injection, Rituximab - Mantle Cell Lymphoma | Phase 3 | Recruiting | InnoCare Pharma Inc. | 476 | 2024-05-29 | 2024-12-27 |
| Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma Zanubrutinib, Rituximab, Patient Observation - Mantle Cell Lymphoma | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 421 | 2023-10-20 | 2026-10-02 |
| A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma Zilovertamab, Ibrutinib, Placebo - Lymphoma, Mantle-Cell, Lymphoma | Phase 3 | Withdrawn | Oncternal Therapeutics, Inc | 2023-03-01 | 2023-04-21 | |
| A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma parsaclisib, rituximab, bendamustine - Mantle Cell Lymphoma | Phase 3 | Withdrawn | Incyte Corporation | 2022-03-11 | 2022-04-29 | |
| Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 Cells, Fludarabine-based chemotherapy + CAR-T-CD19 Cells - Diffuse Large B Cell Lymphoma, Burkitt Lymphoma | Phase 3 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 24 | 2021-09-14 | 2023-07-25 |
| Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies - High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified | Phase 3 | Unknown | Shandong Provincial Hospital | 130 | 2021-04-15 | 2021-11-19 |
| Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) Pirtobrutinib, Ibrutinib, Acalabrutinib - Lymphoma, Mantle-Cell | Phase 3 | Active not recruiting | Loxo Oncology, Inc. | 500 | 2021-04-08 | 2026-09-23 |
| Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX, R-CHOP; R-DA-EPOCH; R-HD MTX - High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | Phase 3 | Unknown | Shandong Provincial Hospital | 160 | 2021-03-01 | 2021-12-21 |
| A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation zanubrutinib, bendamustine, rituximab - Mantle Cell Lymphoma; Non-Hodgkin Lymphoma | Phase 3 | Active not recruiting | BeOne Medicines | 510 | 2019-08-20 | 2026-09-30 |
| Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspirate - Mantle Cell Lymphoma | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 689 | 2017-11-27 | 2026-09-14 |
| Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL) Ibrutinib, Venetoclax, Placebo Oral tablet to match Venetoclax - Mantle-Cell Lymphoma | Phase 3 | Completed | Pharmacyclics LLC. | 366 | 2017-06-19 | 2025-07-22 |
| A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL Acalabrutinib, Bendamustine, Rituximab - Lymphoma, Mantle Cell | Phase 3 | Active not recruiting | Acerta Pharma BV | 635 | 2017-04-05 | 2026-10-08 |
| Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Ibrutinib - Chronic Lymphocytic Leukemia, Indolent B-cell Lymphomas | Phase 3 | Unknown | The University of Hong Kong | 62 | 2016-11-01 | 2018-04-12 |
| ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma R-CHOP/R-DHAP, Ibrutinib (Induction), ASCT conditioning - Mantle Cell Lymphoma | Phase 3 | Unknown | Prof. Dr. M. Dreyling (co-chairman) | 870 | 2016-07-01 | 2017-12-19 |
| Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma Ublituximab, Umbralisib, Bendamustine - Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Phase 2 / Phase 3 | Terminated | TG Therapeutics, Inc. | 710 | 2016-05-25 | 2022-07-21 |
| A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma acalabrutinib, ibrutinib, rituximab - Mantle Cell Lymphoma | Phase 3 | Withdrawn | Acerta Pharma BV | 2016-05-01 | 2016-05-13 |
Showing 20 of 86. Sign in to see all of them.
Lymphoma, Non-Hodgkin (54) · Lymphoma, Large B-Cell, Diffuse (49) · Lymphoma, Follicular (48) · Leukemia, Lymphocytic, Chronic, B-Cell (44) · Lymphoma, B-Cell, Marginal Zone (41) · Burkitt Lymphoma (40) · Lymphoma (39) · Lymphoma, Large-Cell, Immunoblastic (39) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (38) · Hodgkin Disease (34) · Multiple Myeloma (28) · Leukemia, Myeloid, Chronic-Phase (26) · Lymphoma, T-Cell, Cutaneous (26) · Leukemia, Myeloid, Accelerated Phase (25)
Hemic and Lymphatic Diseases (86) · Neoplasms by Histologic Type (86) · Immune System Diseases (85) · Immunoproliferative Disorders (85) · Lymphatic Diseases (85) · Lymphoproliferative Disorders (79) · Neoplasms (76) · Lymphoma, B-Cell (50) · Hematologic Diseases (48) · Leukemia, Lymphoid (48) · Lymphoma (47) · Disease Attributes (46) · Pathologic Processes (46) · Pathological Conditions, Signs and Symptoms (46) · Chronic Disease (44)
Rituximab (29) · Cyclophosphamide (16) · Bendamustine Hydrochloride (10) · Doxorubicin (10) · Prednisone (10) · Vincristine (10) · ibrutinib (10) · Radiotherapy (7) · Filgrastim (6) · Peripheral Blood Stem Cell Transplantation (6) · Whole-Body Irradiation (5) · zanubrutinib (5) · Cyclosporine (4) · Etoposide (4) · Lenalidomide (4)
Fred Hutchinson Cancer Center (5) · German High-Grade Non-Hodgkin's Lymphoma Study Group (4) · Alliance for Clinical Trials in Oncology (3) · European Organisation for Research and Treatment of Cancer - EORTC (3) · Janssen Research & Development, LLC (3) · Jonsson Comprehensive Cancer Center (3) · Memorial Sloan Kettering Cancer Center (3) · Acerta Pharma BV (2) · BeOne Medicines (2) · Celgene (2) · European Mantle Cell Lymphoma Network (2) · Gilead Sciences (2) · Prof. Dr. M. Dreyling (co-chairman) (2) · Shandong Provincial Hospital (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2)
United States (49) · Germany (28) · Italy (20) · France (18) · Canada (15) · United Kingdom (15) · China (14) · Poland (14) · Australia (13) · Belgium (13) · Spain (13) · Czechia (11) · Israel (11) · Netherlands (11) · Portugal (9)
Brenda Sandmaier (2) · David J. Straus, MD (2) · John A. Glaspy, MD, MPH (2) · Michael G.M. Pfreundschuh, MD (2) · Michael G.M. Pfreundschuh, MD † (2) · Viola Poeschel, MD (2) · William A. Wegener, MD, PhD (2) · Xin Wang, PhD (2) · Achiel Van Hoof, MD (1) · Alessandro Levis, MD (1) · Barry J.A. Laird, MD (1) · Bertrand Coiffier, MD (1)
PMID 20032498, PMID 24687837, PMID 32499241, PMID 36485104, PMID 15459300, PMID 15598978, PMID 16030029, PMID 16148284, PMID 16710026, PMID 17397698, PMID 17889355, PMID 18065407, PMID 18077791, PMID 18226581, PMID 18293016, PMID 19270260, PMID 20697092, PMID 22157574, PMID 22337718, PMID 22480131, PMID 22873532, PMID 23335369, PMID 23834234, PMID 24493716, PMID 24591201, PMID 25135997, PMID 25142001, PMID 25403207, PMID 25738670, PMID 26022239, PMID 26611473, PMID 26673811, PMID 26700120, PMID 26700123, PMID 26875824, PMID 27020837, PMID 27313086, PMID 28183846, PMID 28398499, PMID 28583031, PMID 28751558, PMID 28935847, PMID 28953447, PMID 29472356, PMID 30348538, PMID 30811293, PMID 31248843, PMID 31537689, PMID 31633999, PMID 31804876
2023 (2), P01CA015396 (2), P30CA006973 (2), P30CA015704 (2), P30CA068485 (2), 2009 (1), 2015 (1), 2017 (1), 2019 (1), P01CA018029 (1), P01CA078902 (1), P30CA015083 (1), P30CA036727 (1), P30CA069533 (1), R01CA112631 (1)